Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.03 USD | +6.11% | -28.33% | -12.42% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.42% | 244M | |
+12.85% | 227B | |
+13.88% | 192B | |
+18.39% | 136B | |
+28.78% | 108B | |
+1.67% | 64.07B | |
+18.24% | 52.1B | |
+7.04% | 51.87B | |
+10.83% | 44.33B | |
+5.94% | 36.75B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Morgan Stanley Upgrades NeuroPace to Equalweight From Underweight, Adjusts Price Target to $6 From $5